Management of Tropical Pulmonary Eosinophilia

Diagnostic Confirmation

The World Health Organization recommends that a diagnosis of tropical pulmonary eosinophilia be confirmed by the presence of characteristic features, including an eosinophil count that typically exceeds 3 × 10⁹/L, which is a hallmark of TPE 1, 2
Filarial serology is strongly positive for Wuchereria bancrofti or Brugia species antibodies and/or antigens, and microfilariae are NOT detected on blood film microscopy, distinguishing TPE from other forms of filariasis 3, 1, 2
Chest radiograph may show interstitial shadowing, reticulonodular or miliary infiltrates, though normal in 20% of cases 1, 2
Pulmonary function tests reveal obstructive pattern early or restrictive pattern in later stages 1

The Centers for Disease Control and Prevention recommends that before administering DEC, co-infection with Onchocerca volvulus and Loa loa microfilaremia must be excluded to prevent life-threatening complications 3, 4
If Loa loa microfilariae are present, use corticosteroids with albendazole first to reduce microfilarial load below 1000/ml before giving DEC 3, 4, 5
Diethylcarbamazine is the definitive treatment for tropical pulmonary eosinophilia, and prompt initiation is critical to prevent progression to irreversible pulmonary fibrosis 3, 1, 2

The American Thoracic Society suggests that corticosteroids may be beneficial for ongoing alveolitis and to prevent pulmonary fibrosis, particularly in patients with delayed diagnosis or severe disease 1, 2, 4
Always exclude strongyloidiasis before initiating steroids, as corticosteroids can precipitate fatal hyperinfection syndrome 1, 2

The European Respiratory Society recommends that bronchodilators may provide symptomatic relief for dyspnea and wheezing during the acute phase 3, 4
Approximately 20% of patients relapse and require re-treatment with a second course of DEC 1, 2
Monitor for relapse with clinical symptoms and eosinophil counts, as 20% will require re-treatment 1, 2

Chest radiograph abnormalities are present in 80% of cases, showing interstitial shadowing, reticulonodular or miliary infiltrates, and clinical presentation includes fever, dry cough, wheeze, and breathlessness, often misdiagnosed as asthma, according to the Journal of Infection 6
The American Thoracic Society recommends considering corticosteroids for ongoing alveolitis and to prevent pulmonary fibrosis, particularly in patients with delayed diagnosis or severe disease, with standard practice being prednisolone 20 mg/day for 5 days initially, with longer courses for chronic cases 6

The Infectious Diseases Society of America suggests using corticosteroids in treatment failures or incomplete responders after standard DEC therapy, with research showing 20-40% failure rates in chronic cases with standard DEC alone 6